<DOC>
	<DOC>NCT01698554</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of bimatoprost solution formulation A compared with bimatoprost solution 0.03% (LATISSEÂ®) and vehicle in the treatment of eyelash hypotrichosis (inadequate eyelashes).</brief_summary>
	<brief_title>Bimatoprost in the Treatment of Eyelash Hypotrichosis</brief_title>
	<detailed_description />
	<mesh_term>Hypotrichosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<criteria>Male and female adult patients with eyelash hypotrichosis (inadequate eyelash growth). Damage to eyelid area (scarring) that may prevent growth of eyelashes Active eye diseases (glaucoma, uveitis, eye infections, chronic blepharitis or severe dry eye) Eye or eyelid surgery (including laser, refractive, intraocular filtering surgery, blepharoplasty) during the 3 months prior to screening Current eyelash implants of any kind Eyelash tint or dye application within 2 months of baseline Eyelash extensions application within 3 months of baseline Use of eyelash growth products within 6 months of baseline Treatments that may affect hair growth (minoxidil, cancer chemotherapeutic agents, etc) within 6 months prior to baseline.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>